Event Title
Analysis of Outcome Measures in Patients with a Fragility Fracture Treated with Forteo
Presentation Type
Oral and/or Visual Presentation
Presenter Major(s)
Physician Assistant Studies
Mentor Information
Theresa Bacon-Baguley, bacon-bt@gvsu.edu
Department
Physician Assistant Studies
Location
Kirkhof Center 2216
Start Date
13-4-2011 11:00 AM
End Date
13-4-2011 11:30 AM
Keywords
Health, Illness, and Healing
Abstract
It is estimated that 10 million Americans have osteoporosis with an additional 34 million having a low bone mass density putting them at risk for the development of osteoporosis. The pathology of osteoporosis revolves around a disruption in bone metabolism which involves a cyclic process of bone resorption (breakdown) and bone formation. These processes, bone resorption and bone formation, can be monitored through serum and/or urine bone markers. One of the treatments for individuals who have sustained a fragility fracture due to osteoporosis is Forteo@, a recombinant human parathyroid hormone. The purpose of this study was to determine the change in bone mineral density and physiologic markers for bone metabolism in patients diagnosed with osteoporosis who were treated with Forteo@.
Analysis of Outcome Measures in Patients with a Fragility Fracture Treated with Forteo
Kirkhof Center 2216
It is estimated that 10 million Americans have osteoporosis with an additional 34 million having a low bone mass density putting them at risk for the development of osteoporosis. The pathology of osteoporosis revolves around a disruption in bone metabolism which involves a cyclic process of bone resorption (breakdown) and bone formation. These processes, bone resorption and bone formation, can be monitored through serum and/or urine bone markers. One of the treatments for individuals who have sustained a fragility fracture due to osteoporosis is Forteo@, a recombinant human parathyroid hormone. The purpose of this study was to determine the change in bone mineral density and physiologic markers for bone metabolism in patients diagnosed with osteoporosis who were treated with Forteo@.